Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.

摘要: Cyclacel Pharmaceuticals, under license from Sankyo Co, is developing the prodrug sapacitabine for potential treatment of cancer. initiated phase I trials prior to Cyclacel's acquisition, and Ib are currently in progress.